Graphite Bio, Inc.
NASDAQ:GRPH
3.18 (USD) • At close March 21, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Graphite Bio, Inc. |
Symbool | GRPH |
Munteenheid | USD |
Prijs | 3.18 |
Beurswaarde | 185,193,342 |
Dividendpercentage | 64.78% |
52-weken bereik | 3.05 - 29.82 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Kimberlee Cobleigh Drapkin CPA, CPA |
Website | https://www.graphitebio.com |
An error occurred while fetching data.
Over Graphite Bio, Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)